Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies
Background: High mobility group box 1 (HMGB1), soluble receptor of advanced glycation end products (sRAGE) and programmed cell death markers PD-1 and PD-L1 are immunogenic serum biomarkers that may serve as novel diagnostic tools for cancer diagnosis. Methods: We investigated the four markers in ser...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/20/5081 |
| _version_ | 1797574355408912384 |
|---|---|
| author | Lars Schröder Alexander B. A. Rupp Kathrin M. E. Gihr Makbule Kobilay Christian M. Domroese Michael R. Mallmann Stefan Holdenrieder |
| author_facet | Lars Schröder Alexander B. A. Rupp Kathrin M. E. Gihr Makbule Kobilay Christian M. Domroese Michael R. Mallmann Stefan Holdenrieder |
| author_sort | Lars Schröder |
| collection | DOAJ |
| description | Background: High mobility group box 1 (HMGB1), soluble receptor of advanced glycation end products (sRAGE) and programmed cell death markers PD-1 and PD-L1 are immunogenic serum biomarkers that may serve as novel diagnostic tools for cancer diagnosis. Methods: We investigated the four markers in sera of 231 women, among them 76 with ovarian cancer, 87 with benign diseases and 68 healthy controls, using enzyme immunoassays. Discrimination between groups was calculated using receiver operating characteristic (ROC) curves and sensitivities at fixed 90% and 95% specificities. Results: HMGB1 levels were significantly elevated and sRAGE levels were decreased in cancer patients as compared to benign and healthy controls. In consequence, the ratio of HMGB1 and sRAGE discriminated best between diagnostic groups. The areas under the curve (AUCs) of the ROC curves for differentiation of cancer vs. healthy were 0.77 for HMGB1, 0.65 for sRAGE and 0.78 for the HMGB1/sRAGE ratio, and slightly lower for the differentiation of cancer vs. benigns with 0.72 for HMGB1, 0.61 for sRAGE and 0.74 for the ratio of both. The highest sensitivities for cancer detection at 90% specificity versus benign diseases were achieved using HMGB1 with 41.3% and the HMGB1/sRAGE ratio with 39.2%, followed by sRAGE with 18.9%. PD-1 showed only minor and PD-L1 no power for discrimination between ovarian cancer and benign diseases. Conclusion: HMGB1 and sRAGE have differential diagnostic potential for ovarian cancer detection and warrant inclusion in further validation studies. |
| first_indexed | 2024-03-10T21:21:47Z |
| format | Article |
| id | doaj.art-9db969a08d1a4da2b3cbe795468133b0 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T21:21:47Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9db969a08d1a4da2b3cbe795468133b02023-11-19T16:00:19ZengMDPI AGCancers2072-66942023-10-011520508110.3390/cancers15205081Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian MalignanciesLars Schröder0Alexander B. A. Rupp1Kathrin M. E. Gihr2Makbule Kobilay3Christian M. Domroese4Michael R. Mallmann5Stefan Holdenrieder6Department of Obstetrics and Gynecology, University Hospital Cologne, 50931 Cologne, GermanyInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, GermanyInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, GermanyInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, GermanyDepartment of Obstetrics and Gynecology, University Hospital Cologne, 50931 Cologne, GermanyDepartment of Obstetrics and Gynecology, University Hospital Cologne, 50931 Cologne, GermanyInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, GermanyBackground: High mobility group box 1 (HMGB1), soluble receptor of advanced glycation end products (sRAGE) and programmed cell death markers PD-1 and PD-L1 are immunogenic serum biomarkers that may serve as novel diagnostic tools for cancer diagnosis. Methods: We investigated the four markers in sera of 231 women, among them 76 with ovarian cancer, 87 with benign diseases and 68 healthy controls, using enzyme immunoassays. Discrimination between groups was calculated using receiver operating characteristic (ROC) curves and sensitivities at fixed 90% and 95% specificities. Results: HMGB1 levels were significantly elevated and sRAGE levels were decreased in cancer patients as compared to benign and healthy controls. In consequence, the ratio of HMGB1 and sRAGE discriminated best between diagnostic groups. The areas under the curve (AUCs) of the ROC curves for differentiation of cancer vs. healthy were 0.77 for HMGB1, 0.65 for sRAGE and 0.78 for the HMGB1/sRAGE ratio, and slightly lower for the differentiation of cancer vs. benigns with 0.72 for HMGB1, 0.61 for sRAGE and 0.74 for the ratio of both. The highest sensitivities for cancer detection at 90% specificity versus benign diseases were achieved using HMGB1 with 41.3% and the HMGB1/sRAGE ratio with 39.2%, followed by sRAGE with 18.9%. PD-1 showed only minor and PD-L1 no power for discrimination between ovarian cancer and benign diseases. Conclusion: HMGB1 and sRAGE have differential diagnostic potential for ovarian cancer detection and warrant inclusion in further validation studies.https://www.mdpi.com/2072-6694/15/20/5081HMGB1RAGEPD1PD-L1ovarian cancerdiagnosis |
| spellingShingle | Lars Schröder Alexander B. A. Rupp Kathrin M. E. Gihr Makbule Kobilay Christian M. Domroese Michael R. Mallmann Stefan Holdenrieder Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies Cancers HMGB1 RAGE PD1 PD-L1 ovarian cancer diagnosis |
| title | Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies |
| title_full | Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies |
| title_fullStr | Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies |
| title_full_unstemmed | Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies |
| title_short | Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies |
| title_sort | immunogenic biomarkers hmgb1 and srage are potential diagnostic tools for ovarian malignancies |
| topic | HMGB1 RAGE PD1 PD-L1 ovarian cancer diagnosis |
| url | https://www.mdpi.com/2072-6694/15/20/5081 |
| work_keys_str_mv | AT larsschroder immunogenicbiomarkershmgb1andsragearepotentialdiagnostictoolsforovarianmalignancies AT alexanderbarupp immunogenicbiomarkershmgb1andsragearepotentialdiagnostictoolsforovarianmalignancies AT kathrinmegihr immunogenicbiomarkershmgb1andsragearepotentialdiagnostictoolsforovarianmalignancies AT makbulekobilay immunogenicbiomarkershmgb1andsragearepotentialdiagnostictoolsforovarianmalignancies AT christianmdomroese immunogenicbiomarkershmgb1andsragearepotentialdiagnostictoolsforovarianmalignancies AT michaelrmallmann immunogenicbiomarkershmgb1andsragearepotentialdiagnostictoolsforovarianmalignancies AT stefanholdenrieder immunogenicbiomarkershmgb1andsragearepotentialdiagnostictoolsforovarianmalignancies |